Silk Road Medical Inc
NASDAQ:SILK

Watchlist Manager
Silk Road Medical Inc Logo
Silk Road Medical Inc
NASDAQ:SILK
Watchlist
Price: 27.49 USD Market Closed
Market Cap: $1.1B

Silk Road Medical Inc
Investor Relations

In the often complex maze of the medical device industry, Silk Road Medical Inc. has carved a distinctive path by addressing a significant healthcare need—reducing the risks associated with carotid artery disease, a major cause of stroke. Founded with a vision of minimizing the invasiveness of medical procedures, this California-based company has innovated a novel approach known as Transcarotid Artery Revascularization (TCAR). Unlike traditional methods, TCAR allows physicians to directly access the carotid artery through a small incision at the neckline. By temporarily reversing blood flow, it prevents any dislodged plaque from traveling to the brain during the procedure. This surgery can be completed in a fraction of the time typically required, providing a crucial advantage in terms of patient safety and recovery.

Silk Road Medical's business model thrives on the production and sale of the specialized instruments that enable this innovative procedure. The company generates revenue primarily through the sale of these proprietary devices, which are designed to be used in conjunction with TCAR surgeries conducted by trained vascular surgeons. Their product line, which includes devices like the ENROUTE Transcarotid Neuroprotection System and the ENROUTE Transcarotid Stent System, is at the heart of their financial success. By offering a solution that blends safety, efficacy, and hospital efficiency, Silk Road Medical not only meets a medical demand but also strategically positions itself in a niche market, capitalizing on the growing adoption of minimally invasive techniques across healthcare systems worldwide.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q1 2024
Call Date
Apr 30, 2024
Q1 2024 Earnings Call
No Analysis Available

This earnings call has not been analyzed yet.

If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.

Request Earnings Call Analysis
Earnings Call Recording
Other Earnings Calls

Management

Mr. Charles S. McKhann
CEO & Director
No Bio Available
Mr. Lucas W. Buchanan
CFO & COO
No Bio Available
Mr. Kevin M. Klemz
Executive VP, Chief Legal Officer & Secretary
No Bio Available
Ms. Erica J. Rogers
Independent Consultant
No Bio Available
Mr. Andrew S. Davis
Chief Commercial Officer
No Bio Available
Mr. Richard M. Ruedy
Executive Vice President of Clinical, Regulatory Affairs & Quality Assurance
No Bio Available
Ms. Mhairi L. Jones
Chief Accounting Officer & VP of Finance
No Bio Available
Ms. Tammy Leitsinger
Compliance Officer & VP of Medical Affairs
No Bio Available
Mr. Jorge O'Hara
Vice President of Marketing, Business Development & Strategy
No Bio Available
Ms. Alison Highlander
Vice President of Human Resources
No Bio Available

Contacts

Address
CALIFORNIA
Sunnyvale
1213 Innsbruck Dr
Contacts
+16505669060.0
silkroadmed.com